<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Shilpa Medicare Ltd 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=51125></link><description><![CDATA[Shilpa Medicare Ltd 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Wed, 17 Jun 2026 18:42:39 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2026/06/12_31017998_20260610112246_8121573303.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1036217</link><description><![CDATA[RAICHUR, India & BARCELONA, Spain--(Business Wire/Korea Newswire)--Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain‘s lead program targeting deadly ...]]></description><pubDate>Wed, 10 Jun 2026 14:00:00 +0900</pubDate></item><item><title><![CDATA[실파 메디케어-게이트2브레인, 최초의 뇌암 치료제 개발 위한 전략적 지분 파트너십 체결]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1036219</link><description><![CDATA[라이추르, 인도 & 바르셀로나, 스페인--(Business Wire/뉴스와이어)--실파 메디케어(Shilpa Medicare Limited)(BSE/NSE: SHILPAMED)의 자회사인 실파 바이오케어(Shilpa Biocare Pvt Ltd)가 CNS 치료제에 특화된 바이오텍 기업 게이트2브레인(Gate2Brain, S.L.)과 전략적 지분 파트너십을 체결했다. 실파는 G2B-002에 대한 전략적 주주이자 CMC, 제조 및 규제 파트너가 되며, G2B-002는 두 적응증 모두 미국 FDA와 유럽 EMA로부터 희귀의약품 ...]]></description><pubDate>Wed, 10 Jun 2026 14:00:00 +0900</pubDate></item></channel></rss>